BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25688500)

  • 1. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
    Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
    Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urine cytology and urine markers. Significance for clinical practice].
    Tritschler S; Zaak D; Knuechel R; Stief CG
    Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
    Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
    Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of urinary nucleosides in the diagnosis and surgical monitoring of colorectal cancer].
    Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Yu BM
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):564-8. PubMed ID: 15938925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
    Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
    Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.
    Witjes JA; van der Poel HG; van Balken MR; Debruyne FM; Schalken JA
    Eur Urol; 1998; 33(4):387-91. PubMed ID: 9612682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic role of survivin in urinary bladder cancer.
    Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
    Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
    Kavalieris L; O'Sullivan P; Frampton C; Guilford P; Darling D; Jacobson E; Suttie J; Raman JD; Shariat SF; Lotan Y
    J Urol; 2017 Jun; 197(6):1419-1426. PubMed ID: 27986532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity in urine after transurethral resection is not a predictive marker for recurrence of superficial bladder cancer.
    Wu XX; Kakehi Y; Nishiyama H; Habuchi T; Ogawa O
    Int J Urol; 2003 Feb; 10(2):117-8. PubMed ID: 12588612
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
    Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
    Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
    Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
    Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
    Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
    J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
    Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
    Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.